The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport

Cardiovascular Research

Volumn 77, Issue 4, 2008, Pages 732-739

  Tchoua, Urbain ^a,b   D'Souza, Wilissa ^a   Mukhamedova, Nigora ^a   Blum, Denise ^b   Niesor, Eric ^b   Mizrahi, Jacques ^b   Maugeais, Cyrille ^b   Sviridov, Dmitri ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Atherosclerosis; CETP inhibition; Cholesterol; Cholesteryl ester transfer protein; Lipoproteins; Reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER A1; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TORCETRAPIB;

ADENOVIRUS; ANIMAL CELL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRUS INFECTION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; FECES; HUMANS; LIVER; MACROPHAGES; MICE; QUINOLINES; TIME FACTORS; TRANSFECTION; TRIGLYCERIDES; UP-REGULATION;

EID: 39749120838     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvm087     Document Type: Article

References (28)

1. Sviridov D. Therapeutic targeting of HDL and reverse cholesterol transport. Curr Med Chem Immunol Endocrinol Metab Agents 2005;5:299-309.
2. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-1316.
3. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-167.
4. de Grooth GJ, Klerkx AHEM, Stroes ESG, Stalenhoef AFH, Kastelein JJP, Kuivenhoven JA. A review of CETP and its relation to atherosclerosis. J Lipid Res 2004;45:1967-1974.
5. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 2007;27:257-260.
6. Collet X, Tall AR, Serajuddin H, Guendouzi K, Royer L, Oliveira H et al. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I. J Lipid Res 1999;40:1185-1193.
7. Shimoji E, Zhang B, Fan P, Saku K. Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits. Atherosclerosis 2004;172:247- 257.
8. Zhang Z, Yamashita S, Hirano K, Nakagawa-Toyama Y, Matsuyama A, Nishida M et al. Expression of cholesteryl ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport. Atherosclerosis 2001;159:67-75.
9. Gauthier A, Lau P, Zha X, Milne R, McPherson R. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver. Arterioscler Thromb Vasc Biol 2005;25:2177-2184.
10. Escher G, Hoang A, Georges S, Tchoua U, El-Osta A, Krozowski Z et al. Demethylation using the epigenetic modifier, 5-azacytidine, increases the efficiency of transient transfection of macrophages. J Lipid Res 2005;46:356-365.
11. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998;95:2509-2514.
12. Sattler W, Mohr D, Stocker R. Rapid isolation of lipoproteins and assessment of their peroxidation by high-performance liquid chromatography postcolumn chemiluminescence. Methods Enzymol 1994;233:469-489.
13. Vassiliou G, Benoist F, Lau P, Kavaslar GN, McPherson R. The low density lipoprotein receptor-related protein contributes to selective uptake of high density lipoprotein cholesteryl esters by SW872 liposarcoma cells and primary human adipocytes. J Biol Chem 2001;276:48823-48830.
14. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 2003;108:661-663.
15. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 2006;113:90-97.
16. Chiba H, Akizawa K, Fujisawa S, Osaka-Nakamori T, Iwasaki N, Suzuki H et al. A rapid and simple quantification of human apolipoprotein E-rich high-density lipoproteins in serum. Biochem Med Metab Biol 1992;47:31-37.
17. Hayek T, Chajek-Shaul T, Walsh A, Agellon LB, Moulin P, Tall AR et al. An interaction between the human cholesteryl ester transfer protein (CETP) apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of high density lipoprotein cholesterol levels. J Clin Invest 1992;90:505-510.
18. Spady DK, Woollett LA, Dietschy JM. Regulation of plasma LDL-cholesterol levels by dietary cholesterol and fatty acids. Annu Rev Nutr 1993;13:355-381.
19. Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 2006;47:537-552.
20. Forrester JS, Makkar R, Shah PK. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation 2005;111:1847-1854.
21. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-207.
22. Huang Z, Inazu A, Nohara A, Higashikata T, Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond) 2002;103:587-594.
23. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153-160.
24. Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol 2006;26:2552-2559.
25. Yvan-Charvet L, Matsuura F, Wang N, Bamberger MJ, Nguyen T, Rinninger F et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007;27:1132-1138.
26. Brouillette CG, Anantharamaiah GM, Engler JA, Borhani DW. Structural models of human apolipoprotein A-I: a critical analysis and review. Biochim Biophys Acta 2001;1531:4-46.
27. Reschly EJ, Sorci-Thomas MG, Davidson WS, Meredith SC, Reardon CA, Getz GS. Apolipoprotein A-I alpha-helices 7 and 8 modulate high density lipoprotein subclass distribution. J Biol Chem 2002;277:9645-9654.
28. Tanigawa H, Billheimer JT, Tohyama J-I, Zhang Y, Rothblat G, Rader DJ. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation 2007;116:1267-1273.